We showed that SAV1 mRNA and protein levels in tumor tissues differed significantly from those observed in non-cancerous mucosa, and we were the first to provide evidence that reduced SAV1 protein expression is associated with unfavorable clinicopathological parameters in CRC patients and appears to be involved in the development and progression of CRC. This evidence concerns the gene SAV1 and colorectal carcinoma.